The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Clinical Cancer Research2016Vol. 22(22), pp. 5527–5538
Citations Over TimeTop 1% of 2016 papers
Sen Zhang, Rana Anjum, Rachel M. Squillace, Sara Nadworny, Tianjun Zhou, Jeff Keats, Yaoyu Ning, Scott Wardwell, David F. Miller, Youngchul Song, Lindsey Eichinger, Lauren Moran, Wei‐Sheng Huang, Shuangying Liu, Dong Zou, Yihan Wang, Qurish K. Mohemmad, Hyun Gyung Jang, Emily Ye, Narayana I. Narasimhan, Frank Wang, Juan J. Miret, Xiaotian Zhu, Tim Clackson, David C. Dalgarno, William C. Shakespeare, Victor M. Rivera
Abstract
Brigatinib is a highly potent and selective ALK inhibitor. These findings provide the molecular basis for the promising activity being observed in ALK+, crizotinib-resistant patients with NSCLC being treated with brigatinib in clinical trials. Clin Cancer Res; 22(22); 5527-38. ©2016 AACR.
Related Papers
- → The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models(2016)321 cited
- → How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)(2020)23 cited
- → Abstract 4795: Potency of a new ALK/ROS1 inhibitor TPX-0005 to ALK G1202R mutation and ROS1 G2032R mutation(2018)2 cited
- → Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer(2018)27 cited
- → A New ALK Inhibitor for Crizotinib-Refractory Non–Small-Cell Lung Cancer(2016)